← Leaderboards
Carolyn Williamson
University Of Cape Town
$2,022,958
Attributed
$3,724,337
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $350K · FY2008–24$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,724,337 · 3
By mechanism
R01$3,724,337 · 3
Top collaborators
- Peter B. Gilbert5 shared
- Ronald I Swanstrom5 shared
Most similar at University Of Cape Town
Same institution · by research overlap
- Digby Francis Warner$601,766
- Roger Woodgate$497,205
- Anna-Lise Williamson$1,254,747
- Robert John Wilkinson$5,301,802
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionHiv-1ViralHiv InfectionsAffectAfricanVirusGenotypeCd4 Lymphocyte CountCostMutationLaboratoriesAfrica South Of The SaharaAttenuatedVaccinesCollaborationsAfricaSamplingSiteFutureInvestigationComplexFitnessPrevention
Grant awards (14)
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa$327,638
R01 · FY2024 · AI · contact PI
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa$333,359
R01 · FY2023 · AI · contact PI
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa$336,419
R01 · FY2022 · AI · contact PI
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa$340,958
R01 · FY2021 · AI · contact PI
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa$348,710
R01 · FY2020 · AI · contact PI
Timing of establishment of the HIV latent reservoir in subtype C infected women$328,300
R01 · FY2019 · AI · contact PI
Timing of establishment of the HIV latent reservoir in subtype C infected women$337,374
R01 · FY2018 · AI · contact PI
Timing of establishment of the HIV latent reservoir in subtype C infected women$350,000
R01 · FY2017 · AI · contact PI
Timing of establishment of the HIV latent reservoir in subtype C infected women$350,000
R01 · FY2016 · AI · contact PI
Timing of establishment of the HIV latent reservoir in subtype C infected women$350,000
R01 · FY2015 · AI · contact PI
THE ROLE OF CTL ESCAPE MUTATIONS IN ATTENUATING HIV-1 SUBTYPE C INFECTION$79,389
R01 · FY2011 · AI · contact PI
THE ROLE OF CTL ESCAPE MUTATIONS IN ATTENUATING HIV-1 SUBTYPE C INFECTION$80,190
R01 · FY2010 · AI · contact PI
THE ROLE OF CTL ESCAPE MUTATIONS IN ATTENUATING HIV-1 SUBTYPE C INFECTION$81,000
R01 · FY2009 · AI · contact PI
THE ROLE OF CTL ESCAPE MUTATIONS IN ATTENUATING HIV-1 SUBTYPE C INFECTION$81,000
R01 · FY2008 · AI · contact PI